DTx Pharma

The mood around the BIO-Europe conference in Munich in November was positive as people in the biotech world, or at least 5,500 of them, gathered to talk shop at over 30,000 partnering meetings. Howeve

2023 is wrapping up on a more positive note in terms of biopharma alliances involving South Korean companies. For the majority of this year, sentiment has been bleak amid an absence of major deals wit

Novartis AG ‘s search for interesting early-stage assets is not confined to the usual US and European markets and the Swiss major’s collaboration with South Korea’s Chong Kun Dang Pharmaceutical Corp

A heady start for biopharmaceutical M&A during the first half of 2023 slowed to a crawl during Q3 and particularly the months of August and September, as data recorded by Evaluate show. Biogen, Inc.